

Corporate Profile

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by approximately 200 million patients in 100 markets every day. Headquartered in Israel, Teva is the world's largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has the world-leading innovative treatment for multiple sclerosis as well as late-stage development programs for other disorders of the central nervous system, including movement disorders, migraine, pain and neurodegenerative conditions, as well as a broad portfolio of respiratory products. Teva is leveraging its generics and specialty capabilities in order to seek new ways of addressing unmet patient needs by combining drug development with devices, services and technologies. Teva's net revenues in 2016 were \$21.9 billion. For more information, visit www.tevapharm.com.

Primary IR Contact

Investor Relations

Phone: (215) 591-3034

E-mail:

TevaIRus@tevapharm.com

Recent Headlines

July 24, 2017

Teva Announces the Launch of Generic Vagifem® in the United States

July 20, 2017

NICE Recommends CINQAERO® (reslizumab) for the Treatment of Severe Eosinophilic Asthma

July 13, 2017


Teva Enhances Board of Directors as All Proposals Approved at Annual General Meeting of Shareholders

Upcoming Events

Date	Title
03-Aug-2017	Q2 2017 Teva Pharmaceutical Industries Ltd. Earnings Conference Call

Analyst Estimates / Ratings

Mean Recommendation: 2.5



EPS Trend

		Current	30 Days Ago	90 Days Ago
QTR	Jun 17	1.08	1.12	1.14
QTR	Sep 17	1.25	1.26	1.24
QTR	Dec 17	1.41	1.39	1.37
QTR	Mar 18	1.15	1.14	1.18
FY	Dec 17	4.75	4.77	4.81
FY	Dec 18	4.71	4.72	4.74

SEC Filings

Filing Date	Form
07/24/17	6-K
07/20/17	6-K
07/13/17	6-K
07/11/17	6-K

Financial Reports

Date	
05/11/17	 First Quarter 2017 Earnings Press Release

Presentations

Date	
05/11/17	 Teva First Quarter Results 2017 Presentation

Corporate Officers

Dr. Yitzhak Peterburg
Interim President and CEO

Iris Beck-Codner
Group EVP, Corporate Marketing & Communications

Dipankar Bhattacharjee
President and Chief Executive Officer, Global Generic Medicines Group Group Executive Vice President, Human Resources

Dr. Hafrun Fridriksdottir
Executive Vice President, President of Global Generics R&D

Dr. Michael Hayden
President of Global R&D and Chief Scientific Officer

Dr. Rob Koremans
President and CEO, Global Specialty Medicines

Michael McClellan
Senior Vice President, Interim Chief Financial Officer

Dr. Carlo de Notaristefani
President and Chief Executive Officer, Global Operations

Mark Sabag
Group Executive Vice President, Human Resources

David M. Stark
Group Executive Vice President, Chief Legal Officer

Nir Baron
Executive Vice President, Chief Internal Auditor